Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination

被引:8
作者
Keeshan, Alexa [1 ,2 ]
Galipeau, Yannick [3 ]
Heiskanen, Aliisa [1 ,2 ]
Collins, Erin [2 ]
Mccluskie, Pauline S. [4 ]
Arnold, Corey [4 ]
Saginur, Raphael [5 ]
Booth, Ronald [6 ]
Little, Julian [2 ]
Mcguinty, Michaeline [7 ]
Buchan, C. Arianne [1 ,7 ,8 ]
Crawley, Anglea [8 ,9 ,10 ]
Langlois, Marc-Andre [10 ,11 ]
Cooper, Curtis [1 ,8 ,10 ,12 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa, ON, Canada
[2] Univ Ottawa, Sch Epidemiol & Publ Hlth, Fac Med, Ottawa, ON, Canada
[3] Univ Ottawa, Dept Biochem, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada
[5] Ottawa Hosp, Dept Med, Ottawa, ON, Canada
[6] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada
[7] Ottawa Hosp, Dept Med, Div Infect Dis, Ottawa, ON, Canada
[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[9] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada
[10] Coronavirus Variants Rapid Response Network, Ottawa, ON, Canada
[11] Univ Ottawa, Biochem Microbiol & Immunol, Ottawa, ON, Canada
[12] Ottawa Hosp Res Inst, Clin Epidemiol Program, Div Infect Dis, Ottawa, ON, Canada
基金
加拿大健康研究院;
关键词
COVID-19; immunology; safety;
D O I
10.1136/bmjopen-2023-077714
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundPredictors of COVID-19 vaccine immunogenicity and the influence of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection require elucidation.MethodsStop the Spread Ottawa is a prospective cohort of individuals at-risk for or who have been infected with SARS-CoV-2, initially enrolled for 10 months beginning October 2020. This cohort was enriched for public-facing workers. This analysis focuses on safety and immunogenicity of the initial two doses of COVID-19 vaccine.ResultsPost-vaccination data with blood specimens were available for 930 participants. 22.8% were SARS-CoV2 infected prior to the first vaccine dose. Cohort characteristics include: median age 44 (IQR: 22-56), 66.6% women, 89.0% white, 83.2% employed. 38.1% reported two or more comorbidities and 30.8% reported immune compromising condition(s). Over 95% had detectable IgG levels against the spike and receptor binding domain (RBD) 3 months post second vaccine dose. By multivariable analysis, increasing age and high-level immune compromise predicted diminishing IgG spike and RBD titres at month 3 post second dose. IgG spike and RBD titres were higher immediately post vaccination in those with SARS-CoV-2 infection prior to first vaccination and spike titres were higher at 6 months in those with wider time intervals between dose 1 and 2. IgG spike and RBD titres and neutralisation were generally similar by sex, weight and whether receiving homogeneous or heterogeneous combinations of vaccines. Common symptoms post dose 1 vaccine included fatigue (64.7%), injection site pain (47.5%), headache (27.2%), fever/chills (26.2%) and body aches (25.3%). These symptoms were similar with subsequent doses.ConclusionThe initial two COVID-19 vaccine doses are safe, well-tolerated and highly immunogenic across a broad spectrum of vaccine recipients including those working in public facing environments.
引用
收藏
页数:14
相关论文
共 27 条
[11]  
Government of Canada, 2022, COVID-19 vaccine: Canadian immunization guide (for health professionals)
[12]   Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review [J].
Kreuzberger, Nina ;
Hirsch, Caroline ;
Andreas, Marike ;
Boehm, Lena ;
Broeckelmann, Paul J. ;
Di Cristanziano, Veronica ;
Golinski, Martin ;
Hausinger, Renate Ilona ;
Mellinghoff, Sibylle ;
Lange, Berit ;
Lischetzki, Tina ;
Kappler, Verena ;
Mikolajewska, Agata ;
Monsef, Ina ;
Park, Yun Soo ;
Piechotta, Vanessa ;
Schmaderer, Christoph ;
Stegemann, Miriam ;
Vanshylla, Kanika ;
Weber, Florencia ;
Weibel, Stephanie ;
Stephani, Caspar ;
Skoetz, Nicole .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (08)
[13]   COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021 [J].
Kriss, Jennifer L. ;
Reynolds, Laura E. ;
Wang, Alice ;
Stokley, Shannon ;
Cole, Matthew M. ;
Harris, LaTreace Q. ;
Shaw, Lauren K. ;
Black, Carla L. ;
Singleton, James A. ;
Fitter, David L. ;
Rose, Dale A. ;
Ritchey, Matthew D. ;
Toblin, Robin L. .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (11) :389-395
[14]   Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis [J].
Li, Zejun ;
Liu, Shouhuan ;
Li, Fengming ;
Li, Yifeng ;
Li, Yilin ;
Peng, Pu ;
Li, Sai ;
He, Li ;
Liu, Tieqiao .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[15]   Covid-19: Assess the effects of extending Pfizer vaccine dosing interval, expert urges [J].
Mahase, Elisabeth .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 372 :n162
[16]   Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review [J].
Napuri, Norka I. ;
Curcio, Daniel ;
Swerdlow, David L. ;
Srivastava, Amit .
INFECTIOUS DISEASES AND THERAPY, 2022, 11 (04) :1391-1414
[17]  
National Advisory Committee on Immunization (NACI), 2020, Archived: guidance on the Prioritization of initial doses of COVID-19 Vaccine(S)
[18]  
National Advisory Committee on Immunization (NACI), 2022, Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada
[19]  
National Advisory Committee on Immunization (NACI, 2021, Archived 5: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
[20]   Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis [J].
Nejad, Mohammad-Mehdi Mehrabi ;
Moosaie, Fatemeh ;
Dehghanbanadaki, Hojat ;
Ghadery, Abdolkarim Haji ;
Shabani, Mahya ;
Tabary, Mohammadreza ;
Aryannejad, Armin ;
SeyedAlinaghi, SeyedAhmad ;
Rezaei, Nima .
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)